CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Biological/Vaccine: Angiotensin peptide (1-7) derived plasmaWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)


Name (Synonyms) Correlation
drug896 Digital intervention Wiki 1.00
drug1413 Information-only intervention Wiki 1.00

Correlated MeSH Terms (3)


Name (Synonyms) Correlation
D001248 Asthenopia NIH 1.00
D013180 Sprains and Strains NIH 0.71
D001008 Anxiety Disorders NIH 0.15

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 Evaluation of the Possible Role of Angiotensin Peptide (1-7) on Treatment of COVID-19

Novel Coronavirus is reported to cause COVID-19, recently. It's known that this virus uses ACE (angiotensin converting enzyme) 2 receptors to enter human cells and also blocks the activity of ACE 2. Upon these data the investigators hypothesize that, mortal hyper-inflammation state which is shown in COVID-19 cases, can be a result of angiotensin peptide (1-7) deficiency. Therefore, the aim of this study is to evaluate the possible effect of angiotensin peptide (1-7) supplementation on treatment of COVID-19 cases.

NCT04375124 COVID-19 Biological: Biological/Vaccine: Angiotensin peptide (1-7) derived plasma

Primary Outcomes

Description: mortality rates in two groups will be compared

Measure: mortality

Time: 4 months


No related HPO nodes (Using clinical trials)